Crisol-Deza DA, Zurita-Borja JL, Crisol-Deza YG

Language: Spanish
References: 24
Page:
PDF size: 399.79 Kb.

ABSTRACT

Rheumatoid arthritis is a systemic chronic inflammatory disease that affects 0.4% to 1% of Latin America, manifested by chronic pain, joint destruction and premature death, affecting mainly women. Using the Health Assessment Questionnaire score, a count of swollen joints, presence of rheumatoid nodules, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein and erosions in radiography, were associated with the choice of the first treatment with disease-modifying antirheumatic drugs (DMARDs). To determine the main studies that ensure efficacy towards the development of rheumatoid arthritis refractory to conventional treatment. The literature search was carried out by means of an exploration of articles in PubMed and SciELO; Original and review articles were considered, published in English and Spanish, making use of the descriptors, a preliminary reading of the articles was carried out with the aim ofSelect those that fit our purpose, the documents that had information with the formal aspects, were included in our review, that is, a rigorous reading, which selected a total of 24 articles. It is at this point that clinical observation has made it possible to describe that not all patients have the same course of evolution of the disease, even with standardized treatments worldwide, and when evaluating the outcomes of the disease it is suggested that there must be characteristics of each patients who cause their disease to cause more damage in their evolution compared to other patients.

REFERENCES

1. Massardo L. Artritis reumatoide temprana. Rev Méd Chile. 2008;136(11):1468-75. DOI: http://dx.doi.org/10.4067/S0034-98872008001100015

2. Atsumi T, Yamamoto K, Takeuchi T, Yamanka H, Ishiguro N, Tanaka Y, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases. 2016 [Acceso 06/05/2020];75(1):75-83. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26139005/

3. Song X, Lin Q. Genomics, transcriptomics and proteomics to elucidate the pathogenesis of rheumatoid arthritis. Rheumatol Int. 2017 [Acceso 16/07/2020];37(8):1257-65. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28493174

4. Scherer H, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020;110:102400. DOI: https://dx.doi.org/10.1016/j.jaut.2019.102400

5. Rais R, Saeed M, Haider R. Rheumatoid arthritis clinical features and management strategies at an urban tertiary facility in Pakistan. J Pak Med Assoc. 2014 [Acceso 21/06/2020];64(12):1435-7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25842598

6. Aletaha D. Precision medicine and management of rheumatoid arthritis. J Autoimmun. 2020;32(27):e674. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/32276742

7. Verstappen SMM. The impact of socio-economic status in rheumatoid arthritis. Rheumatology (Oxford). 2017 [Acceso 21/06/2020];56(7):1051-2. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/27940587

8. Castro SMB, Moya AMGS, Mora LM. Aproximación de discapacidad en artritis reumatoide. Resultados de un programa de atención integral. Rev Colomb Reumatol. 2017 [Acceso 21/06/2020];24(3):138-44. Disponible en: Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232017000300138

9. Malm K, Bergman S, Andersson M, Bremander A. Predictors of severe self-reported disability in RA in a long-term follow-up study. Disability and Rehabilitation. 2015 [Acceso 21/06/2020];37(8):686-91. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/25036855/

10. de Cock D, Hyrich K. Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. Best Practice & Research Clinical Rheumatology. 2018 [Acceso 21/06/2020];32(6):869-86. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1521694219300464

11. Singh JA, Saag KG, Bridges Jr L, Akl EA, Raveendhara RB, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology. 2016 [Acceso 21/06/2020];68(1):1-26. Disponible en: Disponible en: https://www.rheumatology.org/Portals/0/Files/ACR%202015%20RA%20Guideline.pdf

12. Dumusc A, So A. Complications and systemic manifestations of rheumatoid arthritis. Rev Med Suisse. 2014 [Acceso 21/06/2020];10(421):592-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24701711

13. Østergaard M, Møller-Bisgaard S. Rheumatoid arthritis: Is imaging needed to define remission in rheumatoid arthritis? Nat Rev Rheumatol. 2014 [Acceso 21/06/2020];10(6):326-8. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24752184

14. Rais R, Saeed M, Haider R. Rheumatoid arthritis clinical features and management strategies at an urban tertiary facility in Pakistan. J Pak Med Assoc. 2014 [Acceso 21/06/2020];64(12):1435-7. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25842598

15. Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. N C Med J. 2017 [Acceso 21/06/2020];78(5):337-40. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28963273

16. Hyndman IJ. Rheumatoid arthritis: past, present and future approaches to treating the disease. Int J Rheum Dis. 2017 [Acceso 21/06/2020];20(4):417-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26845360/

17. Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist. 2016;21(12):1471-82. DOI: http://dx.doi.org/10.1634/theoncologist.2015-0164

18. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685-699. DOI: http://dx.doi.org/10.1136/annrheumdis-2019-216655

19. Remuzgo-Martínez S, Genre F, López-Mejías R, Ubilla B, Mijares V, Pina T, et al. Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis. Sci. 2016;6:29713. DOI: http://dx.doi.org/10.1038/srep29713

20. Yamanaka H. Diagnosis and treatment of rheumatoid arthritis: toward the best practice. How to use the guideline in the management of rheumatoid arthritis? Clin Calcium. 2018 [Acceso 21/06/2020];28(5):607-10. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/29731453

21. González OZ, Egüez MJ, Fusté JC, Reyes ME, Borges LJ, González OL. Caracterización clínico-epidemiológica de pacientes con artritis reumatoide: características tomográficas y evolución. Rev Finlay. 2015 [Acceso 21/06/2020];5(4):264-74. Disponible en: Disponible en: http://scielo.sld.cu/pdf/rf/v5n4/rf06405.pdf

22. Rachapalli SM, Williams R, Walsh DA, Young A, Kiely PD, Choy EH. First-line DMARD choice in early rheumatoid arthritis (do prognostic factors play a role? Rheumatology. 2018 [Acceso 21/06/2020];49(7):1267-71. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/20008093

23. Yu-Hsiang H, Ming-Shi C. IL - 20 in rheumatoid arthritis. Drug Discovery Today. 2017 [Acceso 21/06/2020];22(6):960-4. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913811/

24. Audo R, Daien C, Papon L, Lukas C, Vittecoq O, Hahne M, et al. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2015 [Acceso 21/06/2020];17(1):1-8. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518710/